Recurrent aphthous stomatitis (RAS), commonly referred to as aphthous ulcer stomatitis, is a prevalent chronic inflammatory condition of the oral mucosa characterized by recurrent, painful ulcerations. Although benign and self-limiting, the condition significantly affects oral intake, speech, and quality of life. The etiology is multifactorial, involving immune dysregulation, nutritional deficiencies, genetic predisposition, and local triggers.
We report the case of a 32-year-old female presenting with recurrent painful oral ulcers for 6 months, affecting eating and daily activities. Clinical examination revealed multiple shallow ulcers with erythematous halos on the buccal mucosa and tongue. Laboratory investigations indicated iron deficiency and low vitamin B12 levels. The patient was managed with topical corticosteroids, oral supplements, and supportive care, resulting in symptomatic relief and reduced recurrence frequency.
This case emphasizes the importance of identifying underlying systemic factors, implementing targeted therapy, and adopting a holistic management approach in recurrent aphthous stomatitis.
Recurrent aphthous stomatitis (RAS) is one of the most common disorders affecting the oral mucosa, with a prevalence ranging from 5% to 25% in the general population. It is characterized by recurrent episodes of painful, round or oval ulcers with a yellowish base and erythematous margins, typically affecting non-keratinized mucosal surfaces such as the buccal mucosa, labial mucosa, and tongue.
RAS is broadly classified into three types: minor, major, and herpetiform ulcers. Minor aphthae are the most common, accounting for approximately 80–85% of cases. The condition usually begins in childhood or adolescence and tends to decrease in frequency with age.
The exact pathogenesis remains unclear but is believed to involve a T-cell-mediated immune response leading to mucosal destruction. Contributing factors include nutritional deficiencies (iron, vitamin B12, folate), stress, hormonal changes, food sensitivities, and systemic conditions such as celiac disease and inflammatory bowel disease.
Despite its benign nature, RAS can significantly impair quality of life due to pain and recurrent episodes. Early recognition and identification of underlying causes are essential for effective management and prevention of recurrence.
Patient History
A 32-year-old female presented to the outpatient department with:
There was no history of fever, weight loss, or systemic illness. The patient reported increased stress levels due to occupational factors.
Medical history revealed no chronic diseases. There was no history of similar lesions in childhood.
Dietary history suggested inadequate intake of green leafy vegetables and animal protein. There was no history of tobacco or alcohol use.
Family history was non-contributory.
Oral Examination



Systemic Examination
Based on clinical presentation, the following were considered:
The absence of vesicles, fungal plaques, and systemic symptoms favored a diagnosis of aphthous ulcers.
Laboratory Tests

Other Tests
A diagnosis of recurrent aphthous stomatitis (minor type) associated with nutritional deficiency was established based on clinical features and laboratory findings.

The treatment plan focused on:
Medical Management
Supportive Measures
Follow-Up
At 1 Month
At 3 Months
At 6 Months
Pathophysiology
RAS is considered an immune-mediated condition involving T-cell activation and cytokine release, leading to epithelial damage.
Key mechanisms include:
Etiology
Contributing factors include:
In this case, nutritional deficiency and stress were significant contributors.
Epidemiology
Major Aphthae
Herpetiform Ulcers
Diagnostic Considerations
Diagnosis is primarily clinical and includes:
Biopsy is reserved for atypical or non-healing ulcers.
Systemic Therapy
Nutritional Therapy
Emerging Therapies
Although benign, RAS can lead to:
The prognosis is generally good, with most cases resolving spontaneously. However, recurrence is common.
Factors influencing prognosis:
Recurrent aphthous stomatitis is a common yet often distressing oral condition with multifactorial etiology. This case highlights the importance of a comprehensive approach, including identification of underlying nutritional deficiencies and appropriate therapeutic intervention.
Topical therapy combined with nutritional supplementation and lifestyle modification can significantly reduce symptom severity and recurrence. Patient education and regular follow-up are crucial for long-term management.
With ongoing research into immunological pathways and targeted therapies, future treatment strategies may offer more definitive control of this recurrent condition.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Number of cancer survivors in the US reaches 18.6 million—projected to exceed 22 million by 2035
2.
When Should Immunocompromised Individuals Receive a COVID Booster?
3.
Novel biomarker has potential for predicting and treating skin cancer metastasis
4.
Taking Charge of Your Cancer Journey.
5.
Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists
1.
Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection
2.
The Statistical Imperative: Navigating Trends, Precision, and Innovation in Gynecologic Oncology 2025
3.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
4.
Cowden Syndrome and Cancer: Understanding the Risk Factors
5.
Cemiplimab: A Revolutionary Drug For Treating Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
2.
Efficient Management of First line ALK-rearranged NSCLC
3.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
5.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation